Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.54 |
| ▸ | FABP7 | O15540 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065675 | 0.85 | FABP5 (0.52) | FABP5FABP7KDM4EALDH1A1MAPT | |
| SCHEMBL3219970 | 0.83 | FABP5 (0.49) | FABP5FABP7ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30928197 | 0.83 | FABP5 (0.58) | FABP5FABP7KDM4EALDH1A1KMT2A | |
| SCHEMBL29677774 | 0.83 | SMN1; SMN2 (0.63) | FABP5FABP7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL119502 | 0.83 | SMN1; SMN2 (0.63) | FABP5FABP7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29400785 | 0.83 | SMN1; SMN2 (0.63) | FABP5FABP7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30062804 | 0.82 | FABP5 (0.57) | FABP5FABP7ALDH1A1MAPTKMT2A | |
| SCHEMBL14626557 | 0.81 | FABP5 (0.60) | FABP5FABP7ALDH1A1MAPTKMT2A | |
| SCHEMBL15884802 | 0.81 | SMN1; SMN2 (0.53) | FABP5FABP7KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL800040 | 0.81 | SMN1; SMN2 (0.53) | FABP5FABP7KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8258304-B2 | N-aryl piperidine substituted biphenylcarboxamides | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-04 | — | — | US | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | MEERPOEL LIEVEN | 2009-06-18 | — | — | US | disclosed |
| EP-1896086-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1536796-B1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2007005491-A1 | HYDRAZIDE CONJUGATES AS IMAGING AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1536796-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004017969-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES AS INHIBITORS OF APOLIPOPROTEIN B SECRETION | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156623-A1 | N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES | LIPC, PNLIP, GPR119 | FABP5 213/4885FABP7 379/4885KDM4E 944/4885 |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | FABP5 3439/4885FABP7 2712/4885KDM4E 2358/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | FABP5 4471/4885FABP7 4585/4885KDM4E 1212/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | FABP5 1735/4885FABP7 900/4885KDM4E 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.